Background and objective: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia. Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) compared with placebo in patients with IPF in two replicate trials (INPULSIS
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia with an unknown cause.
1,2 IPF is a rare disease that is fatal with a median survival time of 2-3 years from diagnosis. 3 In an epidemiological study in Japan based
SUMMARY AT A GLANCE
This pre-specified subgroup analysis of two Phase III, randomized, placebo-controlled trials (INPULSIS ® ) involving 205 sites in 24 countries including 25 Japanese sites revealed that the efficacy and safety profiles of nintedanib in Japanese patients with idiopathic pulmonary fibrosis were similar to those observed in the overall population of both trials.
on clinical records, the annual incidence of IPF was 2.23 per 100 000. 4 The clinical course of IPF in individual patients is variable and unpredictable; some patients progress rapidly, others have periods of relative stability punctuated by acute exacerbations (AEs) and others progress relatively slowly. 3 AEs of IPF are events of respiratory deterioration of unidentified cause that occur in 5-10% of patients annually and are associated with a very poor outcome. 5 AEs are possibly a leading cause of death in patients with IPF.
Nintedanib is an intracellular kinase inhibitor 6 that blocks the kinase activity of fibroblast growth factor, platelet-derived growth factor and vascular endothelial growth factor receptors. 7 To date, nintedanib has been approved for the treatment of IPF in, for example, the United States of America, Europe and Japan following the results of the Phase II trial (TOMORROW) 8 and two replicate Phase III trials (INPULSIS ® ). 9, 10 The INPULSIS ® trials were two replicate, randomized, double-blinded, placebo-controlled trials performed in 24 countries including Japan, which showed that nintedanib slows disease progression by consistently reducing the annual rate of decline in forced vital capacity (FVC) in patients with IPF. In the past, safety concerns related to, for example, drug-induced pneumonia, have been raised in Japanese patients treated with molecular targeted medicines. 11 To assess the efficacy and safety of nintedanib in Japanese patients and to evaluate the consistency of the results with those for the overall population, we report the results of prespecified subgroup analyses of the Japanese patients in the INPULSIS ® trials.
9,10

METHODS
Trial design
This report describes the results of a subgroup analysis of 126 Japanese patients from 25 sites in the international INPULSIS ® -1 and INPULSIS ® -2 trials (NCT01335464 and NCT01335477 at ClinicalTrials. gov). 9, 10 The present analyses were pre-specified for the regulatory submission in Japan. Both trials were conducted in accordance with principles of the Declaration of Helsinki and the Harmonised Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonisation and were approved by local authorities and ethics committees/institutional review boards at each participating site.
Patients
The full eligibility criteria are reported elsewhere. 9, 10 Briefly, patients aged ≥40 years diagnosed with IPF based upon the most recent ATS/ERS/JRS/ALAT (American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association) guideline 1 within 5 years of enrolment were eligible if they met the following criteria: FVC ≥50% of the predicted value, a diffusion capacity of the lung for carbon monoxide (DL CO ) of 30-79% of the predicted value and HRCT of the chest was performed ≤12 months before enrolment.
Treatments
Eligible patients were randomized in a 3:2 ratio to receive either 150 mg of nintedanib bid or placebo for 52 weeks. Patients could receive up to 15 mg/day of prednisone or an equivalent drug if the dose had been stable for ≥8 weeks before screening; patients receiving other therapies for IPF, including pirfenidone, highdose prednisone, azathioprine, N-acetylcysteine and any investigational treatments for IPF, were excluded.
After 6 months of treatment, patients whose condition had deteriorated according to the criteria in the protocol could receive azathioprine, cyclophosphamide, cyclosporine, N-acetylcysteine or prednisone at >15 mg/day or the equivalent. For patients with AE reported by an investigator at any time during the trial, the above-mentioned treatments could be started or the dose increased, as deemed appropriate by the investigator. Pirfenidone was not permitted during the study.
The dose of nintedanib could be interrupted or reduced from 150 to 100 mg bid to manage adverse events. The dose could be restored to 150 mg bid once the adverse event had been reversible. Dose reductions or interruptions were also allowed in the placebo group.
End points
The trial comprised a screening period followed by a 52-week treatment period and a 4-week follow-up period (Fig. S1, Supplementary Information) . Visits during the treatment period were scheduled at 0 (baseline), 2, 4, 6, 12, 18, 24, 30, 36, 44 and 52 weeks. Patients who discontinued treatment prematurely were asked to attend all scheduled visits, including planned examinations.
The primary end point was the annual rate of decline in FVC over 52 weeks (millilitres per year), and the key secondary end points were time to the first AE over 52 weeks (as reported by the investigator) and changes from baseline in St George's Respiratory Questionnaire (SGRQ) total score at week 52. 12 Safety was assessed by means of clinical and laboratory evaluations, including adverse events.
Spirometry was performed at each visit except at 18, 30 and 44 weeks. Spirometric tests were performed and evaluated according to the ATS and ERS criteria 13 using equipment provided by the sponsor. All results were centrally reviewed.
The SGRQ was completed at baseline and at weeks 6, 12, 24 and 52. Laboratory tests were performed at each visit and analyses were done at central laboratory services. The investigators were provided with recommendations for the management of diarrhoea and elevated liver enzymes.
Statistical analysis
The primary analysis used to estimate the treatment effect in the overall population was repeated in Japanese patients to estimate the treatment effect within the Japanese patients as previously described, 9,10 and hence determine whether the results in the overall population could be extrapolated to Japanese patients.
In addition, the terms subgroup (Japanese and nonJapanese) and an interaction term treatment × time × subgroup were added in the main model to test the treatment × time × subgroup interaction for the primary end point. From this model, the P-value of the interaction term treatment × time × subgroup was provided. 9, 10 To test the treatment × subgroup interaction for the key secondary end points, the terms subgroup and an interaction term treatment × subgroup were added in the main model. From this model, the P-value of the interaction term treatment × subgroup was provided. The interaction P-value provides a measure of supportive evidence of consistency.
RESULTS
Patients
Of the 1066 patients who participated in the INPULSIS ® trials, 126 were Japanese (n = 76 in the nintedanib group and n = 50 in the placebo group) (Table S1 (Supplementary Information), Fig. 1 ). More Japanese patients in the nintedanib group prematurely discontinued treatment compared with the placebo group (28.9% vs 22.0%), mostly because of an adverse event (25.0% vs 18.0%). More than 80% of Japanese patients attended all visits up to week 52 in each group.
The baseline characteristics of Japanese patients were generally comparable between the nintedanib and placebo groups (Table 1) . No major differences in baseline characteristics were observed between Japanese patients and the overall population, except for body weight and absolute FVC values, which were slightly lower in Japanese patients than in the overall population. Differences were also observed for baseline systemic corticoid therapy use, which was less frequent in Japanese patients, and SGRQ total score, which was lower in Japanese patients than in the overall population.
Annual rate of FVC decline
The annual rate of the FVC decline in Japanese patients is shown in Figure 2 . Among Japanese patients, the adjusted annual rate of decline in FVC was −135.9 mL/ year in the nintedanib group and −267.7 mL/year in the placebo group (difference: 131.9; 95% CI: 50.7, 213.1 mL/year). The treatment effect of nintedanib on the annual rate of FVC decline in Japanese patients was consistent with the treatment effect in the overall population (109.9 mL/year (95% CI: 75.9, 144.0)). A further analysis of Japanese patients compared with the subgroup of non-Japanese patients showed no statistically significant treatment × time × subgroup interaction (P = 0.4483), indicating that the effect of nintedanib was not different between Japanese and non-Japanese patients. 
First AE
The number of Japanese patients with at least one investigator-reported AE was 3 (3.9%) in the nintedanib group and 6 (12.0%) in the placebo group (Fig. 3) . The hazard ratio for time to first AE in Japanese patients was 0.25 (95% CI: 0.06, 1.02). The treatment effect of nintedanib on the time to first AE in Japanese patients was generally consistent with the treatment effect in 
The INPULSIS
® trials: Japanese patients the overall population (0.64; 95% CI: 0.39, 1.05). When compared with the subgroup of non-Japanese patients, no statistically significant treatment × subgroup interaction was observed (P = 0.3274), indicating that the effect of nintedanib was not different between Japanese and non-Japanese patients. The numbers of Japanese patients with an adjudicated confirmed/suspected AE were 2 (2.6%) in the nintedanib group and 5 (10.0%) in the placebo group.
SGRQ total score
As shown in Figure 4 , the adjusted mean change from baseline in SGRQ total score at week 52 in Japanese patients was 5.81 in the nintedanib group and 9.68 in the placebo group (difference: −3.87; 95% CI: −8.51, 0.76). The treatment effect of nintedanib for change from baseline in SGRQ total score at week 52 in Japanese patients was generally consistent with the treatment effect in the overall population (difference: −1.43; 95% CI: −3.09, 0.23). When compared with the subgroup of nonJapanese patients, no statistically significant treatment × subgroup interaction was observed (P = 0.7721), indicating that the effect of nintedanib was not different between Japanese and non-Japanese patients.
Safety
Adverse events are summarized in Table 2 . The frequencies of patients with severe adverse events and serious adverse events were comparable between the nintedanib and placebo groups in Japanese patients, as in the overall population. The frequency of Japanese patients with adverse events leading to treatment discontinuation was slightly greater in the nintedanib group than in the placebo group, consistent with the results for the overall population.
The most frequently reported adverse events in the nintedanib group compared with the placebo group included diarrhoea, nausea, decreased appetite, abnormal hepatic function and increased hepatic enzyme. Diarrhoea was the most frequent adverse event and occurred in 75.0% of patients (57/76). The characteristics of diarrhoea are summarized in Table S2 Proportion of patients with ≥1 acute exacerbation (%) Proportion of patients with an acute exacerbation (AE) and the hazard ratio for the time to the first event in Japanese patients (A) and in the overall study population (B). AEs were defined as events that met all of the following criteria: unexplained worsening/development of dyspnoea within the previous 30 days; new diffuse pulmonary infiltrates visualized by chest radiography, HRCT, or both, or the development of parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the preceding visit and exclusion of any known causes of acute worsening, including infection, left heart failure, pulmonary embolism and any identifiable cause of acute lung injury, in accordance with routine clinical practice and microbiologic studies. A blinded adjudication committee reviewed all cases that, according to the investigator, fulfilled the above criteria. The adjudication committee classified each reported case as 'confirmed', 'suspected' or 'not' acute idiopathic pulmonary fibrosis (IPF) exacerbation.
(Supplementary Information). Two of the patients with diarrhoea (3.5%) in the nintedanib group and none (0.0%) in the placebo group discontinued treatment because of diarrhoea. The intensity of diarrhoea was mild to moderate and was reversible in all but three patients (94.7%, 54/57). The frequencies of patients with abnormal hepatic function and increased hepatic enzyme in the nintedanib group were greater in Japanese patients (18.4% and 15.8%, respectively) than in the overall population (2.7% and 3.3%, respectively). However, the frequencies of patients with elevated levels of aspartate transaminase (AST) and alanine transaminase (ALT; categorized as three, five or eight times the upper limit of normal (ULN)) were similar between Japanese patients and the overall population (Tables 2, S3 (Supplementary Information)). Two patients (2.6%) discontinued because of increased hepatic enzyme and none (0.0%) discontinued because of abnormal hepatic function. There were no cases that met Hy's law criteria for evaluating liverrelated adverse events.
14
DISCUSSION
Here, we examined the efficacy and safety of nintedanib for the treatment of IPF in Japanese patients in the INPULSIS ® trials.
9,10
The treatment effect of nintedanib on the primary end point and key secondary end points in Japanese patients was consistent with the treatment effect in the overall population. Differences in baseline characteristics have been observed between the overall population and Japanese population in body weight, absolute FVC values, systemic corticosteroid use and SGRQ total score. Taking into account the comparable treatment effects across subgroups in pre-specified and post hoc subgroup analyses by body weight (<65 kg vs ≥65 kg), predicted FVC% (≤70% vs >70%, ≤80% vs >80% and ≤90% vs >90%), systemic corticoid therapy use (yes vs no) and SGRQ total score (≤40 vs >40), as previously reported, [15] [16] [17] [18] [19] it is reasonable to conclude that these differences do not affect the efficacy of nintedanib observed in Japanese patients. Thus, we think that the efficacy of nintedanib observed in the overall population can be extrapolated to Japanese patients.
The proportion of Japanese patients with at least one investigator-reported AE was numerically higher compared with the overall population in the placebo group (12.0% vs 7.6%). However, given the low numbers of events in this subpopulation, this finding needs to be interpreted with caution. The concordance rate between investigator-reported AE and adjudicated AE tended to be better in Japanese patients (77.8% (7/9) vs 48.3% (29/60) in the overall population), which may suggest that the participating Japanese investigators 
The INPULSIS
® trials: Japanese patients had a good understanding of the concept of AE of IPF. Adjudicated evaluation of AEs may provide a more accurate assessment of nintedanib than analysis of all investigator-reported AEs, which include 'false positives' and may lead to a dilution of the effect of nintedanib. 20 Therefore, a consensus on the definition of AEs in IPF patients is urgently needed to facilitate research in future clinical trials. 21 The adverse event profile was similar between Japanese patients and the overall population. The most frequently reported adverse event in the nintedanib group was diarrhoea. However, few patients discontinued treatment because of diarrhoea, indicating that the recommendations for the management of adverse events (i.e. dose reduction, treatment interruption, prophylactic therapy and symptomatic therapy) limited the incidence of permanent treatment discontinuations owing to diarrhoea.
In these analyses, the frequency of patients with liverrelated adverse events (i.e. by preferred term) in the nintedanib group was slightly greater in Japanese patients than in the overall population. This difference might be associated with the lower body weight of Japanese patients. However, when we classified the laboratory test values according to their levels as three, five or eight times the ULN, we found no differences in the frequencies of such events between the Japanese patients and the overall population in the nintedanib group. Therefore, marginal changes in the laboratory test values were possibly designated as liver-related adverse events by Japanese investigators. The liver-related adverse events were generally manageable and most of these events were reversible following the appropriate interventions (i.e. dose reduction and treatment interruption). To improve the management of patients with elevated liver enzymes, it is important to investigate hepatic transaminase and bilirubin levels before the initiation of treatment with nintedanib, and to perform periodic monitoring thereafter. Drug-related interstitial lung disease was not reported in the INPULSIS ® trials. A limitation of this subgroup analysis was that results obtained in the relatively small number of Japanese patients may not be generalizable to the overall population of Japanese patients with IPF being treated in clinical practice.
In conclusion, this pooled analysis of the INPULSIS ® trials revealed that the effects of nintedanib on the annual rate of decline in FVC as a measure of disease progression, the time to first AEs and the change from baseline in SGRQ total score in Japanese IPF patients were similar to those observed in the overall population. 9, 10 Although several adverse events, including diarrhoea, nausea, decreased appetite and increase in liver enzymes, were more frequent in the nintedanib group than in the placebo group, the majority of adverse events were mild or moderate in intensity and manageable using appropriate interventions (dose reduction and treatment interruption). The overall safety and tolerability profile in Japanese patients was similar to that in the overall population. 
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